Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent.

Key Business and Financial Updates:

• Corporate Focus and Strategic Positioning: Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is a discovery and development-stage specialty pharmaceutical company focused on improving clinical outcomes for oncology patients undergoing radiation therapy (RT). The Company’s strategy is centered on developing radiation sensitizers designed to enhance the therapeutic effectiveness of RT, particularly in difficult-to-treat cancers where incremental improvements in survival outcomes can be clinically meaningful.
• Phase 2 Trial Progress: Enrollment, Completion Rates, and Tolerability: During the second quarter of 2025, the Company reported continued progress in its Phase 2 clinical trial evaluating Ropidoxuridine (IPdR) for glioblastoma. Patient enrollment in the initial randomized portion reached 63%, reflecting ongoing execution momentum across active treatment sites. Importantly, 72% of enrolled patients have completed all seven treatment cycles, and trial sites have reported the therapy to be well tolerated, supporting ongoing participation and continuation toward trial completion targets.
• Clinical Execution Pathway and Forward Milestones: Management indicated that trial execution is being advanced in coordination with its primary third-party CRO, Theradex Systems, alongside participation from leading U.S. cancer centers. The Company’s stated objective remains the completion of patient enrollment later in 2025, with follow-up monitoring and trial data readouts expected in 2026, positioning the program for a potentially meaningful clinical and value inflection point as efficacy and survival endpoints mature.
• Product Profile and Trial Design Framework: Ropidoxuridine (IPdR), the Company’s lead clinical asset, is being developed as a radiation sensitizer for use in combination with RT in glioblastoma, a highly lethal brain malignancy with limited treatment options. Shuttle Pharma has previously received FDA Orphan Drug Designation, which may provide enhanced regulatory and commercial advantages, including potential market exclusivity upon approval. The Phase 2 trial design includes randomization of 40 patients across two dose cohorts (1,200 mg/day and 960 mg/day) to identify the optimal regimen; thereafter, an additional 14 patients will be enrolled at the selected dose to strengthen statistical validity, with the primary endpoint centered on demonstrating improved survival versus historical controls.
• Financial and Governance Actions Supporting Nasdaq Compliance and Continuity: On the corporate and financial front, the Company ended the quarter with USD 4.8 million in cash, supported by the closing of a USD 4.25 million private placement in June 2025. In parallel, Shuttle Pharma executed a reverse stock split during June 2025 as part of its broader Nasdaq compliance initiative. The Company also strengthened governance through Board leadership changes, including the appointment of George Scorsis as Chairman and the addition of Interim CEO Christopher Cooper to the Board, reinforcing strategic oversight as the Company advances its clinical program and addresses capital and listing-related priorities.

Key Company specific risks for SHPH:

• Clinical trial and regulatory approval risk: SHPH’s investment case remains highly dependent on successful execution of the Phase 2 study for Ropidoxuridine (IPdR) in glioblastoma, and any delay, safety/tolerability concerns, or failure to demonstrate meaningful survival benefit could materially weaken the development pathway and FDA approval prospects.
• Funding / liquidity and dilution risk: Given limited operating scale and cash runway sensitivity, SHPH may require additional capital to complete enrollment, follow-up, and 2026 data readouts, which increases the risk of shareholder dilution, financing at unfavorable terms, and restricted strategic flexibility.
• Nasdaq compliance and microcap volatility risk: Despite the reverse stock split supporting compliance initiatives, SHPH remains exposed to recurring Nasdaq listing pressure if trading levels deteriorate, while also facing high volatility and limited liquidity typical of microcaps, which can amplify downside moves and increase execution risk for investors.

Technical Observation (on the daily chart):

• Trend Structure and Moving Averages: SHPH remains in a broad bearish trend, but the stock is showing early stabilisation, trading slightly above MA-21 (~1.88) and MA-50 (~1.79) near the USD ~2.0 zone, indicating tentative base-building.
• Momentum Indicators (RSI): The RSI (~52.4) signals neutral-to-mildly positive momentum, suggesting selling pressure has eased; however, momentum is not strong enough yet to confirm a sustained bullish reversal.
• Volume and Technical Outlook: Recent sharp volume spikes may reflect accumulation near lows, but confirmation is required; key support lies at USD 1.88–1.79, while resistance near USD 2.30–2.35 remains critical for any upside continuation.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a discovery and development-stage oncology company focused on improving outcomes for cancer patients undergoing radiation therapy through a pipeline led by Ropidoxuridine (IPdR), alongside HDAC inhibitor candidates and prostate cancer diagnostics assets. Operationally, the Company reported continued progress in its Phase 2 glioblastoma study, with enrollment reaching 63% in the initial randomized cohort, 72% of enrolled patients completing all seven treatment cycles, and treatment reported as well tolerated, supporting a constructive execution trajectory toward full enrollment later in 2025 and expected data readouts in 2026. Strategically, IPdR benefits from FDA Orphan Drug Designation and a structured trial design that includes dose optimization followed by additional enrollment to strengthen statistical validity, with the key value driver being survival improvement versus historical controls. Financially, SHPH ended the quarter with USD 4.8 million cash following a USD 4.25 million private placement and implemented a reverse stock split to support Nasdaq compliance, while also enhancing governance through leadership appointments. From a balanced risk perspective, the outlook remains contingent on clinical success and funding capacity, with additional risks tied to dilution needs and microcap/Nasdaq compliance sensitivity; technically, the stock shows early stabilization above short-term moving averages with RSI in neutral territory, but confirmation of reversal requires sustained strength and a breakout above key resistance levels.

As per the above-mentioned price action, important support around USD 1.80- USD2.00, momentum in the stock over the last month, and technical indicators analysis, a “Speculative Buy’ rating has been given for Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH), at the closing price of USD2.03, as of January 27, 2026.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective, and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is January 27, 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.